These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26686699)

  • 1. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
    Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
    Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
    Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
    PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
    Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
    Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.
    Sakai T; Nishida Y; Hamada S; Koike H; Ikuta K; Ota T; Ishiguro N
    Diagn Pathol; 2017 Aug; 12(1):66. PubMed ID: 28851389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-catenin S45F mutation results in apoptotic resistance.
    Braggio D; Zewdu A; Londhe P; Yu P; Lopez G; Batte K; Koller D; Costas Casal de Faria F; Casadei L; Strohecker AM; Lev D; Pollock RE
    Oncogene; 2020 Aug; 39(34):5589-5600. PubMed ID: 32651460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
    Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
    Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
    An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
    PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor.
    Carrillo-García J; Hindi N; Conceicao M; Sala MÁ; Ugalde A; López-Pousa A; Bagué S; Sevilla I; Vicioso L; Ramos R; Martínez-Trufero J; Gómez Mateo MC; Cruz J; Hernández-León CN; Redondo A; Mendiola M; García JM; Hernández JE; Álvarez R; Agra C; de Juan-Ferré A; Valverde C; Cano JM; Sande LM; Pérez-Fidalgo JA; Lavernia J; Marcilla D; Gutiérrez A; Moura DS; Martín-Broto J
    Eur J Cancer; 2024 Sep; 209():114270. PubMed ID: 39142211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI characteristics predict the efficacy of meloxicam treatment in patients with desmoid-type fibromatosis.
    Shimizu K; Hamada S; Sakai T; Ito S; Urakawa H; Arai E; Ikuta K; Koike H; Ishiguro N; Nishida Y
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):751-757. PubMed ID: 31448875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
    Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
    Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifocal occurrence of extra-abdominal desmoid type fibromatosis - A rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case.
    Bekers EM; van Broekhoven DLM; van Dalen T; Bonenkamp JJ; van der Geest ICM; de Rooy JWJ; van Gorp JM; Creytens DH; de Leng WWJ; Scheijen B; Eijkelenboom A; Flucke U
    Ann Diagn Pathol; 2018 Aug; 35():38-41. PubMed ID: 29705714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.
    Nishida Y; Tsukushi S; Urakawa H; Hamada S; Kozawa E; Ikuta K; Ando Y; Ishiguro N
    Int J Clin Oncol; 2015 Dec; 20(6):1211-7. PubMed ID: 25899770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTNNB1 Mutations and Estrogen Receptor Expression in Neuromuscular Choristoma and Its Associated Fibromatosis.
    Carter JM; Howe BM; Hawse JR; Giannini C; Spinner RJ; Fritchie KJ
    Am J Surg Pathol; 2016 Oct; 40(10):1368-74. PubMed ID: 27259010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours.
    Kattentidt Mouravieva AA; Geurts-Giele IR; de Krijger RR; van Noesel MM; van de Ven CP; van den Ouweland AM; Kromosoeto JN; Dinjens WN; Dubbink HJ; Smits R; Wagner A
    Eur J Cancer; 2012 Aug; 48(12):1867-74. PubMed ID: 22305464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data.
    Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ
    Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.
    Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F
    Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
    Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
    Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
    Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
    Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.